Scotland Greenlights More Rare Disease Treatments
Executive Summary
Scotland’s health technology appraisal body has OKd Alynlam’s Onpattro, AstraZeneca's Imfinzi and Takeda’s Alunbrig for use on the Scottish National Health Service.
You may also be interested in...
NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.